NCT00960557已完成1 期
A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden
Mateon Therapeutics1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed carcinoma. Tumor must be relapsed or refractory to standard therapies, or have no acceptable standard therapy.
- •Measurable disease by RECIST criteria.
- •Subjects must be at least 28 days from other investigational therapy and at least 2 weeks after chemotherapy or radiation therapy.
- •Age 18 years or older.
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of less than
- •Life expectancy of greater than 12 weeks.
- •Hemoglobin greater than 10 g/dL.
- •Adequate hepatic function.
- •Adequate renal function.
- •Adequate bone marrow reserve.
- •Able to maintain potassium, calcium and magnesium levels within normal ranges.
- •Must be able to provide written informed consent.
- •All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
- •WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication.
排除标准
- •Uncontrolled CNS metastases.
- •No other active malignancies.
- •Poorly controlled hypertension.
- •Recent history of serious cardiovascular conditions.
- •Recent history of CVA, TIA, or intermittent claudication.
- •Current anticoagulation therapy.
- •History of cardiac arrhythmias.
- •Abnormal ECG findings.
- •Subjects who require concomitant medications which cause QTc prolongation.
- •Major surgery within 30 days of treatment, or minor surgery within 7 days of treatment.
- •Uncontrolled, clinically significant active infection.
- •Subjects who are pregnant or lactating.
- •Subjects with any other intercurrent medical condition.
- •Subjects with a history of solid organ transplant or bone marrow transplant.
研究组 & 干预措施
Combretastatin A1 Diphosphate
Experimental
干预措施: Combretastatin A1 Diphosphate (OXi4503) (Drug)
结局指标
主要结局
To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
时间窗: 6 Months
次要结局
- To determine progression-free survival (PFS).(6 Months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSLeukemia, Myelogenous, AcuteMyelodysplastic SyndromesNCT01085656University of Florida18
已完成
2 期
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT02688647Kadmon Corporation, LLC76
已完成
1 期
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595Healthy VolunteersBacterial InfectionsNCT02134834Meiji Seika Pharma Co., Ltd.40
已完成
1 期
Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate TabletsHealthyNCT06606860Swiss Tropical & Public Health Institute45
招募中
2 期
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCDSickle Cell DiseaseNCT05431088Pfizer389